Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer

Antzeko izenburuak

• Reproducibility of Immunohistochemical Testing of Estrogen Receptors, Progesterone Receptors, Human Epidermal Growth Factor Receptor-2 (HER2) and Ki-67 in Vietnam
  nork: Thai Anh Tu, et al.
  Argitaratua: (2025-11-01)
• Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
  nork: Siddiqui, Mohammad R., et al.
  Argitaratua: (2019)
• Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies
  nork: Erickson, Britt K., et al.
  Argitaratua: (2020)
• Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
  nork: Sarkis, Julien, et al.
  Argitaratua: (2020)
• Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE
  nork: Johnston, Stephen R.D., et al.
  Argitaratua: (2018)